Dossier assessment
Osimertinib - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Osimertinib - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Osimertinib - Benefit assessment according to §35a Social Code Book V
Press releases
Osimertinib in lung cancer: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.
Project details
- Project no.
- A16-14
- Commission
- Commission awarded on 15.03.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed